Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aging (chronic age-related diseases); ii. metabolic (hyperglycemia advanced glycation end products and its receptor (AGE/RAGE) interactions and hyperinsulinemia-insulin resistance (a linking linchpin); iii. oxidative stress (reactive oxygen-nitrogen species); iv. inflammation (peripheral macrophage and central brain microglia); v. vascular (macrovascular accelerated atherosclerosis-vascular stiffening and microvascular NVU/neuroglial remodeling) with resulting impaired cerebral blood flow.
|
31569571 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is accumulating evidence that the AGEs-RAGE interaction plays an important role in accelerated atherosclerosis in diabetes.
|
31378770 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Atorvastatin improves plaque stability in diabetic atherosclerosis through the RAGE pathway.
|
29509268 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
RAGE does not seem to play a major role in the development of NASH or atherosclerosis in a hyperlipidemic mouse model.
|
30323247 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also outline novel treatments targeting the AGE-RAGE axis and specific Nox isoforms, which hold great promise in attenuating the development of diabetes-associated atherosclerosis and diabetic nephropathy.
|
26323666 |
2015 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore these results suggested that first, RAGE activation may be important in mediating AngII-induced atherogenesis, and second, AngII activation is a major pathway in the development of atherosclerosis.
|
23936343 |
2013 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Soluble receptor for advanced glycation end products RAGE (sRAGE), a secretory form of RAGE, plays an important role in suppressing RAGE signals that induce pro-inflammatory gene activation in a range of inflammatory diseases, such as Alzheimer's disease, complications of diabetes mellitus and atherosclerosis.
|
23708564 |
2013 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
RAGE has been extensively implicated in inflammatory states such as atherosclerosis, but the role of S100A12 as its ligand is less clear.
|
19875725 |
2010 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strategies to reduce the ligation of AGEs to their receptors such as agents which reduce AGE accumulation, soluble RAGE which acts as a competitive antagonist to the binding of AGEs to RAGE and genetic deletions of RAGE appear to attenuate diabetes associated atherosclerosis.
|
18473849 |
2008 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
|
17761193 |
2007 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies in rodent models of diabetes suggest that blockade or genetic modification of RAGE suppress diabetes-associated progression of atherosclerosis, exaggerated neointimal expansion consequent to acute arterial injury, and cardiac dysfunction.
|
16305050 |
2004 |